Clinical trial strategy: Fine-tuning the risk-reward profile
Swiss Biotech Insights - 1/2 Day event
Trial design remains a challenge, and development the longest and most expensive component of the Biotech value creation.
The Swiss Biotech Association and Parexel invite you to Lausanne on Sept 19th for this exciting event to address major clinical trial strategy challenges. Hear from world-renowned speakers and discuss the growing complexity of trials while exploring exciting new opportunities including real world data science, adaptive clinical trial design, biomarkers and more.
The Swiss Biotech Association is launching the Swiss biotech Insight event series, designed to cover a portfolio of topics mirroring the biopharma product life cycle, namely from ideation and research to commercialization and patient benefit. The three main areas covered are discovery, development and commercialization.
|Target audience||Biotech, Pharmaceutical and Medtech Companies, Multinationals, SMEs and Start Ups|
|Organizer||Swiss Biotech Association|
|Cost of participating||CHF 50 for Swiss Biotech Association Members and CHF 100 for everyone else|
Dr. Olaf Ritzeler, Director, Rare Diseases External Innovation, Sanofi
Matthias Grossmann, VP, Parexel Early Phase Scientific Affairs
Dr. Andrew Galazka, MD, Senior VP, Head of Global Medical Excellence at Merck
Dr. Jens Wuerthner, Head of Clinical Development, ADC Therapeutics
Dr. Justin Devine, Chief Medical Officer, Synexa Group Life Sciences
Claudia Graeve, VP, Health Advances
Pantelis Vlachos, Principal Strategic Consultant, Cytel Inc
Philippe Menu, McKinsey & Company
Christian Fehr, Relationship Manager Primary Markets, and Valeria Ceccarelli, Head Primary Markets, SIX
Dr. Victor Cheng, Vice President, Technical, Parexel China
Agora Cancer Research Centre
CHUV University Hospital, Rue du Bugnon 25A